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Abstract  
Introduction 
Non-alcoholic fatty liver disease is the commonest cause of liver disease worldwide, and is rapidly 
becoming the leading indication for liver transplantation.  
Sources of data 
Original articles, reviews and meta-analyses, guidelines. 
Areas of agreement  
NAFLD strongly correlates with obesity and insulin resistance; currently the best management 
strategy is weight loss and treatment of the metabolic syndrome. 
Areas of controversy 
Recent data suggest that the presence of fibrosis and not non-alcoholic steatohepatitis (NASH) is the 
predictor of clinical outcome. 
Growing points 
Many phase 2 and 3 trials are underway. Drugs hoped to be effective are obeticholic acid, 
elafibranor, glucagon-like peptide-1 analogues and CCR2/5 inhibitors. 
Areas timely for developing research  
Improved understanding of the pathophysiology of NAFLD should help to us identify which patients 
progress to significant liver disease and to develop therapies to target this population.  
 
KEYWORDS: Non-alcoholic fatty liver disease, cardiovascular disease, NASH, fibrosis, metabolic 
syndrome, obesity, assessment, treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of liver disease in Western 
countries, with an overall prevalence of 25% in the general population1 rising to 70% in the obese 
population2 and those who have type 2 diabetes mellitus2,3.  Moreover, the number of affected 
individuals is expected to increase over the forthcoming years4, in line with rising obesity due to the 
adoption of a high fat diet and sedentary lifestyle.  In the US it has become the second commonest 
cause for liver transplantation and is likely to become the leading cause over the next 10 years5.  This 
review will cover what is already known about the disease, current management strategies, and 
discuss areas of contention requiring further research and development.  
 
PATHOPHYSIOLOGY 
Free fatty acid (FFA) and hepatic triglyceride (TG) accumulation is a cardinal feature of NAFLD, and 
commonly occur in the setting of insulin resistance and obesity.  Liver injury usually occurs in the 
presence of these features, mediated by inflammatory cytokines, mitochondrial dysfunction 
secondary to nutrient excess, and oxidative stress6,7.  The extent of hepatic inflammatory damage is 
also influenced by of extrahepatic factors such as adipose tissue signalling7, the effect of gut 
microbiota8 and polymorphisms such as PNPLA3 and TLF613 which are currently being explored.  
In most patients the only response to obesity/insulin resistance is simple steatosis, or non-alcoholic 
fatty liver (NAFL), which is defined as steatosis ≥5% and is believed to follow a relatively benign 
course.  However, in a proportion of patients with steatosis1 a more profound inflammatory liver 
damage occurs, termed non-alcoholic steatohepatitis (NASH), which is characterised by the presence 
of lobular inflammation and hepatocellular damage (ballooning).  This carries a worse prognosis, 
with 40% developing progressive fibrosis leading to cirrhosis in 10-27%, and hepatocellular 
carcinoma (HCC) in about 4-27% of those with cirrhosis).1,9,10 
NAFLD is also an independent risk factor for cardiovascular disease (CVD) and diabetes mellitus6, and 
indeed, ischaemic heart disease and stroke are the leading cause of morbidity and mortality in 
patients with NAFLD9.  
 
Areas of controversy 
How important is NASH?  
NASH reflects hepatocellular damage and often the commencement of fibrosis progression and yet 
several long term outcomes studies have suggested that it is fibrosis stage, rather than the presence 
of NASH or an elevated NAFLD activity score (NAS) that predict patient outcomes (see table 1)11,12.  
This may be a reflection of retrospective studies with insufficient power and/or it may be that NASH 
is a more dynamic entity which may spontaneously resolve as opposed to fibrosis, the presence of 
which is more intractable.  
 
Growing points 
It is likely that certain single nucleotide polymorphisms (SNPs) predispose some individuals to 
NAFLD.  Genome wide association studies have identified several potentially important genetic 
variants; the polymorphism seen in patatin-like phospholipase domain-containing 3 (PNPLA3) and 
farnesyl diphosphate farnesyl transferase-1 (FDFT-1) appears to be most significant.  A non-
synonymous single nucleotide polymorphism, rs738409 (c.444 C>G, I148M) in palatin-like 
phospholipase domain-containing 3 (PNPLA3), encoding the adiponutrin protein, is linked to 
increased hepatic triglyceride content and increased severity of NASH and fibrosis in NAFLD13.  Three 
other SNPs have been associated with the lobular inflammation phenotype: SNP rs1227756 on 
chromosome 10 in the COL13A1 (and collagen, type XIII, α 1) gene, rs6591182 on chromosome 11, 
and rs887304 on chromosome 12 in the EF-hand calcium binding domain 4B(EFCAB4B) gene, and 
another SNP in transmembrane 6 superfamily member 2 (TM6SF2) (rs58542926 c.449 C>T, E167K) 
also has a strong association with NAFLD and disease progression to fibrosis and cirrhosis13,14.  It is 
therefore possible that in future we will be able to risk stratify patients according to the presence of 
genetic polymorphisms. 
Recently, gut microbiota has been shown to have a potential role in the development of 
steatohepatitis and fibrosis in NAFLD.  Lipopolysaccharides (LPS) from Gram negative gut micro flora 
are absorbed into intestinal capillaries and enter the portal system, activating toll-like receptors 
(TLRs) on hepatocytes, Kupffer cells and hepatic stellate cells and exerting a pro-inflammatory effect.  
The clearance of LPS is believed to be impaired in NAFLD, leading to a cascade of bacterial 
overgrowth, increased intestinal permeability and stimulation of inflammatory cytokines and 
chemokines, resulting in hepatic injury and fibrosis8,15. There is particular interest in Porphyromonas, 
a gram negative coccus that has been associated with several components of the metabolic 
syndrome, as well as complications of chronic liver disease, but more work is needed to establish its 
exact role in the pathogenesis of human NASH8. 
 
 
 
ASSESSMENT 
In a clinical setting, it is important to identify those patients that are at risk of progressive liver 
fibrosis, as these individuals will require regular monitoring, lifestyle interventions and management 
of their cardiovascular risk factors. Notably, most subjects with NAFLD are generally asymptomatic, 
with the diagnosis often made following an incidental finding of a fatty liver on ultrasound scan 
(USS) or abnormal LFTs16. Figure 1 illustrates a suggested pathway for patients presenting with 
abnormal LFTs who are suspected to have NAFLD. 
 Serum markers 
Levels of serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are usually 
increased up to 1.5- to 4-fold but rarely exceed 5 times the upper limit of normal in the setting of 
NAFLD.  Gamma glutamyl transpeptidase (GGT) and alkaline phosphatase levels may also be 
elevated, but the serum prothrombin time, bilirubin level and serum albumin level are normal, 
except in patients with NAFLD-associated cirrhosis.  About a quarter of NAFLD patients may have 
antinuclear antibodies (ANA) in low titres (less than 1:320), and serum ferritin level may be raised in 
20% to 50% of NAFLD patients, which is often associated with more advanced disease9. Plasma 
cytokeratin-18 (CK-18) is a filament protein in the liver, with caspase cleaved fragments released into 
blood stream following hepatocyte injury and apoptosis as seen in the setting of NASH. Levels of CK-
18 fragments have been shown to correlate with histologically confirmed NASH in several groups 
(Area under the receiver operated curve (AUROC) of 0.83 and sensitivity of 77%), although it is not 
clear whether they have the precision to have a diagnostic role or help monitor response to 
therapy17,18.   
The enhanced liver fibrosis (ELF) test combines three candidate serum biomarkers for fibrosis; 
hyaluronic acid (HA), procollagen III amino terminal peptide (PIIINP), and tissue inhibitor of 
metalloproteinase 1 (TIMP-1), which have been shown to correlate with the level of liver fibrosis 
seen histologically. A cut-off of 10.51 has been demonstrated to have a sensitivity of 100% and a 
specificity of 98% for detecting advanced fibrosis19; it is likely that ELF testing will be incorporated 
into upcoming UK guidelines to be used as a screening tool in the primary care setting.  
Where NAFLD is detected, a liver screen is generally performed to exclude autoimmune, viral and 
genetic causes followed by an assessment to determine the presence of NASH or fibrosis in order to 
risk stratify the patient for progression of liver disease. 
 Imaging for steatosis and inflammation 
Ultrasound scan (USS) is the commonest modality for diagnosing liver steatosis, as defined by hyper-
echogenicity of the liver parenchyma relative to the kidney or spleen20, and is widely used due to its 
simplicity, non-invasive nature and low cost21.  It is however highly operator dependant, non-
reproducible, and can be limited by abdominal gas or patient body habitus, but more importantly it 
is unable to distinguish simple steatosis from advanced fibrosis or cirrhosis20 
Use of the FibroScan® device with the controlled attenuation parameter (CAP) facility can also be 
used to assess hepatic steatosis.  Ultrasound signals acquired by the FibroScan® are attenuated by 
liver fat which can be measured using a standard probe, giving a value between 100 and 400 dB/m22. 
One prospective study in 153 patients compared the percentage of steatosis on liver biopsy with 
CAP readings found that using a cut-off of 283 dB/m, the CAP was 76% sensitive, 79% specific, and 
had positive and negative predictive values of 87% and 64%, respectively. The AUROCs of the CAP 
for ≥5%, >33% and >66% steatosis in this study were 0.79, 0.76 and 0.70, respectively23.  A larger 
study by de Ledinghen et al compared CAP readings with histology in 440 patients and had similar 
finding grades of steatosis (>10%, >33% and >66%). AUROCs were 0.79 (95% CI 0.74-0.84, p<0.001), 
0.84 (95% CI 0.80-0.88, p<0.001) and 0.84 (95% CI 0.80-0.88, p<0.001) respectively24. In both studies 
only the M probe was used, and failure rate for those with a BMI >40kg/m2 was 58.4%23,24, although 
an XL probe is now available which has a lower failure rate and has similar accuracy in pilot studies25. 
Magnetic resonance imaging (MRI) techniques and magnetic resonance spectroscopy (MRS) have 
been shown to detect lower levels of steatosis (<5) as well as identify changes in fat content 
accurately.  Magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) is a novel, 
image-based modality that permits quantification of the entire fat content of the liver, and which 
correlates strongly with MR-spectroscopy measured liver fat and histologically-determined steatosis 
grade26.  Multi-parametric magnetic resonance (MR) imaging is another non-invasive technique 
under development and involves a 3 stage process: T1 mapping for fibrosis/inflammation imaging, 
T2 mapping for liver iron quantification, and proton magnetic resonance spectroscopy (1H-MRS) for 
liver fat quantification.  The results allow quantification of hepatic fibrosis, iron, and steatosis and in 
preliminary studies predict clinical outcomes in patients with chronic liver disease27,28.  
 
Imaging for fibrosis 
Transient elastography (TE), through assessment of liver stiffness measurement (LSM) is widely 
available in most secondary or tertiary centres for the assessment of liver fibrosis29.  Several studies 
have provided moderate quality evidence for the diagnostic accuracy of transient elastography over 
a range of thresholds, and an XL probe has being validated for use in obese subjects.  Wong et al 
demonstrated a sensitivity of 91% and a specificity of 75% in for the detection of significant (≥F3) 
fibrosis using a cut off of >7.9kPa30. The same group confirmed efficacy to detect ≥F3 fibrosis in 
those with a BMI ≥30 with a sensitivity and specificity of 90% using a cut off of 7.2 kPa31. Acoustic 
radiation force impulse (ARFI) imaging (ACUSON S2000™; Siemens Medical Solutions, Mountain 
View, CA, USA) is another ultrasound-based method for the assessment of liver stiffness based on 
the measurement of shear waves.  Preliminary studies have shown that using a threshold of 
4.24KPa, advanced fibrosis (stage 3 or 4) is detected with a sensitivity of 90% and specificity of 90%.  
It is comparable to transient elastography, and has the possible benefit that it can be undertaken 
during a routine US assessment32,33.   
Magnetic Resonance Elastography (MRE) has also been shown to be useful for the detection of 
significant fibrosis (stage 2 or above) and cirrhosis in all aetiologies of liver disease, including 
NAFLD34,35.  For detection of significant fibrosis MRE showed 100% sensitivity, 96.5% specificity, and 
98.9% accuracy and 88.2% sensitivity, 91.1% specificity, and 93.5% accuracy for cirrhosis34.  The 
ability to provide a summative assessment of fibrosis of the liver is a major advantage, although as 
with most elastography modalities the presence of significant inflammation can increase 
elastography readings35.    
 
Liver Biopsy  
Liver biopsy remains the gold standard for both diagnosis and staging of disease, with NASH as 
defined by the presence of hepatocellular injury (ballooning, apoptosis/necrosis, presence of 
Mallory’s hyaline, giant mitochondria), and inflammation (neutrophil and other inflammatory cell 
infiltrate)36, being detected solely on histology.  Several scoring systems exist to help quantify these 
histological changes, the commonest being the NASH Clinical Research Network (CRN) classification 
which encompasses the NAFLD activity score (NAS), which grades steatosis, lobular inflammation 
and hepatocellular ballooning, and a 0-4 score for liver fibrosis (see table 1). More recently, the 
steatosis, activity, fibrosis (SAF) score was proposed37, which aims to accurately diagnose NASH and 
reduce inter-observer variability by further defining ballooning according to the size and shape of 
hepatocytes, and lobular inflammation according to the number of inflammatory foci per lobule. 
When used in the Fatty Liver Inhibition of Progression (FLIP) algorithm, patients can be further 
divided into those with NASH and those with simple steatosis37.  Liver histology remains the 
mainstay for outcomes in clinical trials and is required for seeking regulatory approval of new 
therapies. 
 
Areas of controversy 
Should we screen for NAFLD? 
Many physicians advocate screening for NAFLD, and multiple methods have been proposed for this 
purpose, including imaging techniques such as USS, MRI and transient elastography, or using blood 
tests such as the fatty liver index or AST/ALT ratio.  Early identification of patients with or at risk of 
NAFLD may facilitate beneficial changes in lifestyle and prompt aggressive treatment of features of 
the metabolic syndrome, thereby reducing long term morbidity and mortality from both liver and 
cardiovascular disease.  However, given the high prevalence of NAFLD (7-90% depending on the 
population and screening tool used)1, limited treatment options, and the significant financial burden 
involved in screening, robust cost-effectiveness analyses are necessary to support this approach38. 
 
TREATMENT 
Lifestyle modification 
Unhealthy diets, such as those enriched in fructose, trans-fatty acids and saturated fat are believed 
to be associated with the development of NAFLD39.  Dietary sugars such as fructose are used as a 
substrate for lipogenesis leading to hepatic fatty infiltration, inflammation, and possibly fibrosis.  Fat 
consumption, especially cholesterol, and trans or saturated fatty acids have also been shown to be 
steatogenic and seem to increase visceral adiposity40.  A recent review of dietary interventions in 
NAFLD suggested that restriction and modulation of simple and high glycaemic carbohydrates and 
total and saturated fats can improve metabolic parameters such as insulin resistance, decrease liver 
enzymes levels, and reduce the grade of steatosis, independent of weight loss41.  However, few 
studies included liver biopsies, none were randomised control trials, and the authors were unable to 
conclude that benefits of dietary modification were truly independent of weight loss.  Lifestyle 
modification, if successfully implemented, can result in weight loss with improvements in all 
histological aspects of NAFLD. A large prospective cohort study by Vilar-Gomez et al investigated the 
effect of various degrees of weight loss on liver histology in 261 patients, and found that 
improvements in inflammation (resolution of NASH or reduction in NAS score) correlated with the 
magnitude of weight loss41.  Notably a greater degree of weight loss (≥10%) was required for 
improvement in inflammation in those patients deemed higher risk at baseline (female sex, fasting 
glucose >5.5mmol/L, many ballooned cells at baseline, BMI> 35).  Furthermore, those achieving ≥ 10 
% weight reduction were also seen to have regression in fibrosis41.  One of the major challenges with 
lifestyle change once achieved is being able to sustain it for the longer-term which is lacking in 
studies thus far. 
It is likely that a reduction in calorific intake to bring about weight loss is the most beneficial dietary 
modification in NAFLD, and there is little evidence to favour one dietary intervention over another. 
In fact there are no RCTs, systematic reviews or comparative prospective cohort studies investigating 
diet alone, but several trials have shown that dietary intervention in addition to exercise appears to 
be the most effective42.  
Exercise 
Current obesity guidelines recommend 30 minutes of moderate exercise five times weekly43 to aid 
weight loss and improve cardiovascular health.  However, there is no consensus as to what the ideal 
duration or intensity is for NAFLD, and both moderate-intensity aerobic and resistance training have 
been shown to reduce intrahepatic lipid (IHL) independent of weight loss and dietary 
modification44,45.  One study also showed evidence for histological improvements in patients with 
NASH following a 24 week moderate intensity aerobic programme, although greater benefits were 
seen in those who also made dietary modifications46.  Most studies involve regimens of exercise for 
up to 60 minutes thrice weekly, much less than the guidelines for obesity.  However, in most studies, 
the exercise was not monitored and so true level of participation is unknown42.  
There is increasing interest in high-intensity interval training (HIIT), a modified form of sprint interval 
training using high intensity bouts of exercise followed by recovery periods, which has been 
proposed as a less time consuming alternative to continuous moderate intensity alternatives47. 
Studies have demonstrated at least equivalent if not greater improvements in cardiovascular fitness 
with HIIT compared to moderate intensity exercise in a broad range of populations, including those 
with obesity and the metabolic syndrome48.  A meta-analysis of HIIT also showed significant 
improvements in fasting glucose and glycated haemoglobin A1c (HBA1c) in this subgroup of 
volunteers49, suggesting potential improvements in insulin sensitivity.  A recent study of HIIT in 
NAFLD showed a significant improvement in intrahepatic lipid, but no significant changes in 
measurements of insulin resistance (HBA1c, 2-hour insulin, HOMA2-ß, HOMA2-S) following a thrice 
weekly 30 minute HIIT intervention for 12 weeks50.  
` 
Diet supplements/probiotics 
Consumption of omega-3 fatty acid has been found to be low in patients with NAFLD51, and there 
have been several randomised control studies of the benefits of omega 3 polyunsaturated fatty acid 
(PUFA) 'member.help@medicalprotection.orgMany probiotic formulae have been studied in an 
attempt to target potential imbalance in gut microbiome described above, and have shown some 
success in improving hepatic steatosis, ALT levels and transient elastography scores15 in adults.  
Larger studies are needed to confirm these findings, and describe their role and ideal dosage in 
NAFLD.   
 
Alcohol – to drink or not to drink? 
Advice on alcohol consumption in the setting of NAFLD is controversial. Whilst there are data 
suggesting that modest consumption (1 unit/day) is associated with a reduced prevalence of 
NAFLD55 and cardiovascular disease56, other studies refer to the harmful synergy between alcohol 
and obesity57. Pragmatically, most recommend consumption within standard limits with the 
exception of those with advanced fibrosis in whom abstinence is advised. 
 
Caffeine 
For some time, caffeine has been believed to be hepatoprotective, although its potential role in 
NAFLD has been unclear.  A recent meta-analysis of four cross-sectional and two case control studies 
concluded that caffeine from coffee was associated with reduced prevalence of hepatic fibrosis in 
patient NAFLD58.  More studies are needed before recommendations could be made regarding ideal 
daily consumption.   
 
Pharmacotherapy 
There are currently no approved pharmacotherapies for NAFLD, with the main focus being the 
management of components of the metabolic syndrome such as insulin resistance, hypertension and 
hyperlipidaemia.  Hypertension and hyperlipidaemia should generally be managed according to local 
guidelines in the recognition that statins are not only safe in NAFLD but are associated with a 
reduced mortality 12, 59.  There are no particularly favoured agents for control of hypertension, 
although previous studies had suggested that angiotensinogen receptor blockers may have 
additional anti-fibrotic effects60. 
 
A range of medications have been studied specifically in NAFLD with some proceeding into late 
phase trials.  Metformin is the first line agent for T2DM, and reduces the risk of all diabetes-related 
end-points including microvascular disease, myocardial infarction, large vessel disease, and 
cardiovascular mortality, in addition to aiding weight loss61.  Although studies have not 
demonstrated any improvements in liver enzymes or liver histology, there is epidemiological 
evidence to suggest it is associated with a reduced incidence of liver and non-liver malignancies 
including HCC in those with NASH cirrhosis by as much as 7%62.   
 
Pioglitazone 
Pioglitazone improves insulin sensitivity, reduces hepatic steatosis, inflammation, and to a lesser 
degree fibrosis63 in patients with NASH, and has been shown to result in an 18% reduction in death, 
myocardial infarction and stroke in patients with T2DM64.  The PIVENS trial assigned 247 non-
diabetic adults with NASH to receive pioglitazone, vitamin E, or placebo, for 96 weeks. The primary 
outcome was a significant change in histologic features of NASH, as assessed with the use of the 
NASH CRN classification.  Whilst pioglitazone did not meet its primary end-point65, serum alanine 
and aspartate aminotransferase levels were reduced (p<0.001), and there was a reduction in hepatic 
steatosis (p<0.001) and lobular inflammation (p=0.004), but not in fibrosis scores (p=0.12 for 
pioglitazone). Subsequent meta-analyses has also demonstrated efficacy in inducing resolution of 
NASH63.  However, subjects in the PIVENS trial who received pioglitazone gained more weight than 
did those who received vitamin E or placebo65, a side effect seen in several other studies.  
Furthermore, concerns regarding the long-term safety of pioglitazone have limited its use. Two 
meta-analyses have found an increased risk of congestive cardiac failure, despite reductions in other 
cardiovascular mortality.  In the study by Lincoff et al, heart failure was reported in 200 (2.3%) of 
pioglitazone-treated patients compared with 139 (1.8%) control patients (HR, 1.41; 95% CI, 1.14-
1.76; P = .002)64,66.  Concerns have also been raised regarding the risk of bladder cancer, following a 
study demonstrating relative odds ratio of 4.30 (95% CI 2.82-6.52) for pioglitazone compared with 
other antidiabetic medications, based on adverse event reporting to the United States Food and 
Drug Administration (FDA) between 2004 and 200967. There is a possible reduction of bone density 
with pioglitazone; thiazolidinedione use causes PPAR-γ activation which increases bone resorption 
increases while decreasing bone formation, a significant concern as those with diabetes are already 
at increased risk of osteoporosis68.   
Liraglutide 
Liraglutide is a GLP-1 receptor agonist approved for use in diabetes, which has been shown to induce 
improvements in peripheral, hepatic and adipose insulin resistance, alongside reductions in de novo 
lipogenesis69.  In a proof of concept RCT it met its primary end-point and induced resolution of NASH 
in both diabetic and non-diabetic patients70, although further studies are needed to corroborate this 
effect. Use of the higher 3 mg dose of liraglutide in an obese cohort without diabetes over 70 weeks, 
demonstrated significant weight loss in those on liraglutide versus placebo (63.2% vs 27.1% for 5% 
weight loss and 33.1% vs 10.6% for 10% loss, respectively)71.  Side effects were minimal and the 
higher dose appeared well tolerated. 
GFT505 
PPARs are nuclear receptors that play key roles in the regulation of metabolism and inflammation. 
GFT505 is a new dual agonist of the PPARα and δ receptors, and has been shown to improve lipid 
and glucose metabolism in type 2 diabetes mellitus (T2DM), and steatosis, inflammation and fibrosis 
in mouse models of NAFLD72.  A small study (n=22) in an obese population has shown that GFT505 
improved peripheral and hepatic insulin sensitivity, and significantly reduced Insulin-suppressed 
plasma free fatty acid concentrations, fasting plasma triglycerides and LDL cholesterol73.  Post-hoc 
analysis of a recently published randomised phase IIb study showed patients clearing NASH (as 
defined by disappearance of ballooning together with either disappearance of lobular inflammation 
or the persistence of mild lobular inflammation (score of 0 or 1) without worsening of fibrosis) with 
120 mg oral elafibrinor (GFT505).  When compared with placebo, improvement in NASH was more 
pronounced in those with NAS≥4, (19% vs 9%; p=0.013) compared with those with NAS ≤4 (19% vs 
12%; p=0.045), and it is likely that PPAR agonism with have role in pharmacotherapy for NASH in the 
future74,75.  
 
Vitamin E 
Vitamin E is an antioxidant and has potential mechanism to reduce oxidative stress in NASH.  It is the 
most widely investigated antioxidant, and has been shown to improve steatosis and inflammation in 
several RCTs in both diabetic and non-diabetic children and adults76,77.  However, the trials have 
been heterogeneous, comparing different doses of vitamin E against various agents as well as 
placebo, and in two studies the participants had lost weight, making it difficult to draw adequate 
conclusions. Despite meeting the primary end-point in the PIVENS trial, there are persisting concerns 
regarding the risk of prostate cancer and haemorrhagic stroke in higher doses78,79, as well as reports 
of increased all-cause mortality80.  The SELECT study compared selenium vs vitamin E vs placebo for 
a primary outcome of Gleason grade ≥7 prostate cancer, and showed a relative risk of 17% with 
vitamin E.  However, absolute risk was lower at 1.6 per 1000 person-years was 1.6 for vitamin E, and 
it is possible that identifiable SNPs affecting vitamin E metabolism may be responsible for the 
increased risk78. A meta-analysis investigating the effect of vitamin E on the incidence stroke 
reported an increase in the relative risk of haemorrhagic stroke by 22%, while the risk of ischaemic 
stroke was reduced by 10%. Given the severity of outcomes following haemorrhagic stroke, the 
authors could not recommend the use of vitamin E79.  Despite the potential benefits for NASH, the 
longest prospective trial is 2 years77, and given the long term concerns, the risks and benefits of 
therapy must be carefully discussed with patients in clinical practice.  
Obeticholic acid 
Obeticholic acid (OCA) is a synthetic variant of the natural bile acid chenodeoxycholic acid, a potent 
activator of the farnesoid X nuclear receptor, which down-regulates lipogenesis.  A randomised, 
placebo-controlled trial in NAFLD (the FLINT study) demonstrated improvement in histological 
features of NASH (steatosis, hepatocyte ballooning, inflammation) as well as fibrosis81. Increased 
levels of low-density lipoprotein (LDL), and reduced high-density lipoprotein (HDL) were also seen in 
this group, which will need to be monitored in the ongoing phase III study. There was also a high 
incidence of pruritus (23%) which may be an important consideration for a condition with minimal 
symptoms81. 
Bariatric surgery  
Bariatric surgery offers an invasive but effective means of sustainable weight loss.  There have been 
no RCTs investigating the benefits of bariatric surgery in NAFLD, but meta-analysis of cohort studies 
suggests an improvement in steatosis by 91.6%, steatohepatitis by 81.3%, and fibrosis, 65.5%, 
following bariatric surgery82.  Furthermore, improvements in insulin resistance, dyslipidaemia and 
other obesity related comorbidities have been demonstrated.  No single technique is recommended 
for NAFLD but bypass procedures are believed to be the most effective for weight loss83.  RCTs and 
long term follow up studies are required to fully evaluate the risks and benefits of surgery over 
lifestyle modification and pharmacotherapy. 
 
Growing points  
LOXL2 antibody/inhibitors 
LOXL2 is one of a family of enzymes involved in modifying the extracellular matrix, promoting cross-
linking of cellular collagen, and fibrosis84.  Serum LOXL2 levels have been shown to correlate with 
fibrosis in NAFLD, and both an antibody and inhibitor and have been developed, with phase 2b trials 
underway for the former (clinical trials.gov identifier: NCT01672866, NCT01672879). 
 
Vascular adhesion protein-1 
The adhesion molecule vascular adhesion protein-1 (VAP-1) is a membrane-bound amine oxidase 
that promotes leukocyte recruitment to the liver, and the soluble form (sVAP-1) accounts for most 
circulating monoamine oxidase activity, has insulin-like effects, and can initiate oxidative stress.  An 
absence or blockade of functional VAP-1 in murine hepatic injury models has been shown to reduce 
inflammatory cell recruitment to the liver and attenuate fibrosis. Furthermore, serum sVAP-1 levels 
are elevated in patients with NAFLD compared with those in control individuals, and targeting VAP-1 
is believed to have therapeutic potential for NAFLD and other chronic fibrotic liver diseases85. 
 
CCR2/CCR5 antagonist 
The C-C chemokine receptor types 2 and 5 (CCR2 and CCR5), and their respective ligands, C-C 
chemokine ligand types 2 (CCL2/monocyte chemo attractant protein-1 [MCP-1]) and 5 
(CCL5/RANTES) are involved in recruitment of inflammatory cells to the liver and activation of 
hepatic stellate cells which promote fibrosis86.  Inhibition of CCR2 or CCR5 in murine models of liver 
injury demonstrated reduction in fibrosis; an oral dual CCR2/CCR5 antagonist (Cenicriviroc), has now 
been developed and a phase IIb trial is currently underway87.  
 
Liver transplantation  
Transplantation for NAFLD is rising, and with it, expertise in the selection and management of both 
graft and patient peri-operatively88.  Patients often have significant comorbidities, yet a recent meta-
analysis showed a tendency towards death from cardiovascular disease or sepsis, but otherwise 
similar 5 year outcomes for NASH recipients compared with other aetiologies89. Higher rates of renal 
dysfunction are observed in patients with NASH after transplantation, and therefore use of 
mycophenolate and lower serum levels of Tacrolimus are recommended90. 
 
CONCLUSIONS 
NAFLD is the fastest growing cause for liver disease worldwide, and in the light of the obesity 
epidemic, shows no sign of waning. Liver steatosis alone is relatively benign, but the presence of 
fibrosis has significant implications for cardiovascular and liver related morbidity and mortality.  The 
factors determining development of steatohepatitis and fibrosis are poorly understood, and warrant 
further investigation.  Nevertheless, identifying those with NASH and fibrosis is crucial, as these 
patients should usually be managed within a secondary care setting, and may benefit from 
pharmacological and non-pharmacological interventions, regular modification of risk factors, and 
participation in clinical trials.  
There are currently no non-invasive tests for steatohepatitis, but several for fibrosis.  Currently, once 
patients at high risk group have been identified, management is focussed on encouraging weight loss 
and managing features of the metabolic syndrome, in an attempt to halt progression of the disease 
and reduce cardiovascular mortality.  Exercise and weight loss remain the most effective strategy for 
disease management, but is limited by the ability to sustain lifestyle changes in this population 
group.  Identifying dietary and exercise regimens that are the easiest to adopt and lead to 
longstanding lifestyle reform will improve liver and cardiovascular outcomes. These would ideally be 
tailored to individual needs and abilities, but this is a resource-heavy approach, and may not be 
practicable in most healthcare systems. 
 
Trials for pharmacological agents have historically been limited by small study cohort sizes, a dearth 
of high quality studies, and concerns regarding efficacy and side effects.  However, there is now 
multiple large phase II/III RCT in progress with both new and existing agents, with the FDA assigning 
breakthrough designation for several of them in light of the significant clinical unmet need in NASH. . 
NAFLD is a highly complex condition with multiple parallel pathways and thus it is likely that therapy 
will be personalised and consist of multiple therapies. 
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Table 1. NASH CRN histological scoring system.  
NAFLD Activity Score (NAS) (0–8) 
Sum of scores for steatosis, lobular inﬂammation and hepatocellular ballooning 
Steatosis (0–3)  
      0 = <5% hepatocytes involved  
      1 = 5–33% hepatocytes involved  
      2 = 33–66% hepatocytes involved  
      3 = >66% hepatocytes involved 
Lobular Inﬂammation (0–3)  
      0 = none  
      1 = <2 foci per ·200 ﬁeld  
      2 = 2–4 foci per ·200 ﬁeld  
      3 = >4 foci per ·200 ﬁeld 
Hepatocyte ballooning (0–2)  
      0 = none  
      1 = few ballooned cells  
      2 = many cells ⁄ prominent ballooning 
Score  
      ≥5  Probable or definite NASH 
      3-4 Uncertain 
      ≤2  Not NASH 
Fibrosis stage 
1 Perisinusoidal or periportal  
      1a = Mild, zone 3, perisinusoidal 
      1b = Moderate, zone 3, perisinusoidal  
      1c = Portal / periportal ﬁbrosis only 
2 Perisinusoidal and portal / periportal ﬁbrosis 
3 Bridging ﬁbrosis 
4 Cirrhosis 
 
